About the Authors
- Rikio Suzuki
-
Contributed equally to this work with: Rikio Suzuki, Shohei Kikuchi, Takeshi Harada
Affiliations Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America, Department of Hematology/Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan
- Shohei Kikuchi
-
Contributed equally to this work with: Rikio Suzuki, Shohei Kikuchi, Takeshi Harada
Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America
- Takeshi Harada
-
Contributed equally to this work with: Rikio Suzuki, Shohei Kikuchi, Takeshi Harada
Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America
- Naoya Mimura
-
Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America
- Jiro Minami
-
Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America
- Hiroto Ohguchi
-
Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America
- Yasuhiro Yoshida
-
Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America
- Morihiko Sagawa
-
Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America
- Gullu Gorgun
-
Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America
- Diana Cirstea
-
Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America
- Francesca Cottini
-
Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America
- Jana Jakubikova
-
Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America
- Yu-Tzu Tai
-
Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America
- Dharminder Chauhan
-
Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America
- Paul G. Richardson
-
Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America
- Nikhil Munshi
-
Affiliation VA Boston Healthcare System, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America
- Kiyoshi Ando
-
Affiliation Department of Hematology/Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan
- Teruhiro Utsugi
-
Affiliation Tsukuba Research Center, Taiho Pharmaceutical Co., Ltd., Tsukuba, Japan
- Teru Hideshima
-
Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America
- Kenneth C. Anderson
-
* E-mail: kenneth_anderson@dfci.harvard.edu
Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America
Competing Interests
The authors of this manuscript have the following competing interests: T.U. is an employee at Taiho Pharmaceutical Co., Ltd. Y.-T.T. is a consultant for Onyx. D.C. is a consultant for Oncopeptides AB. P.G.R. is a member of the advisory boards for Celgene, Millennium, Johnson & Johnson, Novartis, and Bristol-Myers Squibb. N.M. is a member of the advisory boards for Millennium, Celgene, and Novartis. T.H. is a consultant for Acetylon Pharmaceuticals. K.C.A. is a member of the advisory boards for Onyx, Celgene, Gilead, and Sanofi-Aventis, and is a scientific founder of Acetylon and Oncopep. J.M. receives research funding from Bristol-Myers Squibb. The other authors declare no conflicts of interest. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: RS SK T. Harada D. Cirstea JJ YTT D. Chauhan KA TU T. Hideshima KCA. Performed the experiments: RS SK T. Harada N. Mimura JM HO YY MS GG FC T. Hideshima. Analyzed the data: RS SK T. Harada D. Chauhan PGR N. Munshi T. Hideshima KCA. Wrote the paper: RS SK T. Harada T. Hideshima KCA.